Yüklüyor......
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
SIMPLE SUMMARY: The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rates. These agents are actively being investigated earlier in the sequence of therapi...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7601361/ https://ncbi.nlm.nih.gov/pubmed/33050054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102887 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|